308080.Kq

308080.KQ has a current ratio of 20.04, indicating strong liquidity, but its debt-to-equity ratio of 0.17 suggests a relatively low level of leverage. The company's liquidity position is further supported by its total assets of 54,275,047,510 KRW, which significantly exceed its total liabilities of 10,554,805,640 KRW. However, the company's operating cash flow is negative at -13,817,801,910 KRW, which may indicate challenges in generating sufficient cash from operations.

The company's profitability is weak, with a return on equity of -0.3733 and a return on assets of -0.3007, both of which are significantly below the industry median for biotechnology firms. These metrics suggest that the company is not effectively utilizing its equity and assets to generate profits. The operating income is also negative at -17,105,833,060 KRW, further highlighting the company's financial challenges.

308080.KQ's revenue is concentrated in its core pharmaceutical and medical research activities, with no disclosed geographic diversification. The company's revenue of 22,674,300 KRW is derived from a single business segment, which may expose it to higher operational and market risks. The lack of geographic diversification could limit the company's ability to mitigate regional economic downturns or regulatory changes.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The negative operating and net income figures suggest that the company is not currently expanding its operations or increasing its market share. The company's capital expenditure of -821,754,000 KRW indicates a reduction in investment in long-term assets, which may affect its future growth potential.

The company faces several risk factors, including a negative net cash position after subtracting total debt. This liquidity risk is compounded by the company's negative operating and free cash flows, which may limit its ability to fund operations and meet financial obligations. The dilution risk is currently low, as the number of shares outstanding has not changed between basic and diluted shares. However, the company's negative net income and operating cash flow may necessitate future equity issuances, which could dilute existing shareholders.

Recent events, such as the company's financial performance and capital structure, suggest that it is facing significant operational and financial challenges. The company's negative operating income and cash flows indicate that it may need to seek additional financing or restructure its operations to improve its financial position.